This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $984,500 to Brigham & Women's Hospital, Inc. to conduct a pilot randomized controlled trial evaluating the use of the drug semaglutide as an adjunct treatment to buprenorphine for individuals with opioid use disorder (OUD). The primary objective is to assess whether semaglutide, an FDA-approved medication for diabetes and obesity, can help reduce cue-induced craving in OUD patients receiving standard buprenorphine therapy. The study will also evaluate the safety and tolerability of semaglutide over the 12-week trial period. If successful, the results could lay the groundwork for future large-scale clinical trials to determine the efficacy of semaglutide as a novel pharmacotherapy intervention for OUD. The award period runs from Sep 30, 2024 to Aug 31, 2026.
Generated 1/28/25, 9:43 AM